NEW YORK--(BUSINESS WIRE)--Ophthotech today announced that it will report its fourth quarter and full year 2018 financial and operating results on Tuesday, February 26, 2019.
Tue Feb 19, 2019 15:00
BOSTON & HAMILTON, Ontario--(BUSINESS WIRE)--Fusion Pharma Announces First Patient Dosing in a Phase 1 Clinical Trial of [225Ac]-FPI-1434 Injection in Patients with Advanced Solid Tumors
Tue Feb 19, 2019 15:00
IRVINE, Calif.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24NVUS&src=ctag" target="_blank"gt;$NVUSlt;/agt; lt;a href="https://twitter.com/hashtag/otitismedia?src=hash" target="_blank"gt;#otitismedialt;/agt;--Novus Therapeutics announces that it has dosed the first patients in a phase 2a trial of OP0201, the lead product candidate for otitis media.
Tue Feb 19, 2019 15:00
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced it will present preclinical GvHD data from its ALPN-101 program at the 2019 Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR (TCT Meetings) in Houston, TX. Additionally, Alpine has strengthened its Scientific Advisory Board with the addition of i
Tue Feb 19, 2019 14:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Wednesday, February 27, 2019 at 5:00 p.m. EST to discuss its fourth quarter and full year 2018 operating and financial results. The webcast will be accessible under "Events & Presentations" in the Investors/Media page of the company's website at www.acceleronpharma.com. Individuals can participate in the conference call by dialing 877-312-5848 (domestic) or 25
Tue Feb 19, 2019 14:00
KENILWORTH, N.J.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24MRK&src=ctag" target="_blank"gt;$MRKlt;/agt; lt;a href="https://twitter.com/hashtag/MRK?src=hash" target="_blank"gt;#MRKlt;/agt;--FDA Approves Merck’s KEYTRUDA® for the Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Node(s) Following Complete Resection
Tue Feb 19, 2019 13:45
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2018. “Eight years ago, Sage was founded to address the innovation void in CNS drug development. Today we are establishing Sage as a CNS leader by building multiple franchise opp
Tue Feb 19, 2019 13:30
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, disclosed today positive top-line results from the ARTISAN-SNM pivotal study, designed to gain marketing approval from the U.S. Food & Drug Administration (“FDA”) for the Axonics r-SNM® System1. The clinical study demon
Tue Feb 19, 2019 13:00
HUNTINGTON BEACH, Calif.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/asrm?src=hash" target="_blank"gt;#asrmlt;/agt;--CiceroDx, Inc., a women’s healthcare diagnostic company, is pleased to announce the publication of a pivotal study demonstrating the effectiveness of both medical or surgical treatment in unexplained infertility patients with abnormal endometrial BCL6 expression. The paper, Medical or surgical treatment before embryo transfer improves outcomes in women with abnormal endometrial...
Tue Feb 19, 2019 10:00
LONDON--(BUSINESS WIRE)--St. Bartholomew's Hospital is a key study site for CALM-2 clinical trial to explore treatment of high blood pressure.
Tue Feb 19, 2019 09:15
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for polatuzumab vedotin in combination with bendamustine plus Rituxan® (rituximab) (BR) for the treatment of people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The FDA is expected to make a decision
Tue Feb 19, 2019 08:00
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Applications (NDAs) and granted Priority Review for entrectinib for the treatment of adult and pediatric patients with neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive, locally advanced or metastatic solid tumors who have either progressed following prior therapies or
Tue Feb 19, 2019 08:00
LAWRENCEVILLE, N.J.--(BUSINESS WIRE)--Asana BioSciences will present ASN002 data correlating microbiome changes with clinical efficacy for atopic dermatitis at the AAD Annual Congress
Mon Feb 18, 2019 15:00
CAMPBELL, Calif.--(BUSINESS WIRE)--Saama Technologies unveils three new capabilities for award-winning Life Science Analytics Cloud at SCOPE 2019.
Mon Feb 18, 2019 15:00
SKOKIE, Ill.--(BUSINESS WIRE)--Exicure, Inc. (OTCQB:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that its CEO, Dr. David Giljohann, will present at SMi’s RNA Therapeutics 2019 Conference being held February 20-21, 2019 at the Copthorne Tara Hotel in London, UK. Dr. Giljohann’s presentation titled “Spherical Nucleic Acids: Clinical Progress” will occur on Wednesday, February 20, 2019 at 9:10 am GMT. About Ex
Mon Feb 18, 2019 14:00
ADELAIDE, Australia--(BUSINESS WIRE)--Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a global, clinical stage biopharmaceutical company, announces that an additional data analysis conducted in Sweden by Pharmetheus AB showed a statistically significant response when drug exposure versus response was measured in the Phase 2 PTSD Trial (referred to as the RESTORE trial). The exposure-response analysis uses patient blood levels of the drug, regardless of the administered dose, to relate drug exposure t
Mon Feb 18, 2019 13:00
DUBLIN & CAMBRIDGE, England--(BUSINESS WIRE)--Inflazome (inflazome.com), the pioneering inflammasome company, announces the appointment of distinguished scientist, Prof. Marco Colonna M.D. to its Scientific Advisory Board. Prof. Colonna has deep expertise and extensive experience in innate immunity. His team is responsible for the innovative discovery of Triggering Receptors Expressed on Myeloid cells (TREM), important regulators of the innate immune response. Prof. Colonna is currently investi
Mon Feb 18, 2019 09:00
悉尼--(BUSINESS WIRE)--前列腺癌症诊断公司Minomic International Ltd荣幸地宣布：公司已经和美国临床实验室改进法案修正案（CLIA）认证的“高端复杂性”实验室Cirrus Dx正式签署协议。借此，美国的临床医生和病患届时将可受惠于Minomic公司的新型前列腺癌检测技术MiCheck®。根据协议，等到内部验证流程完毕，Cirrus Dx就可以把MiCheck® 作为其实验室自研产品（Laboratory Developed Test，LDT），在它位于美国马里兰州洛克维尔的实验室里对收到的病患样本进行前列腺癌症检测。 这是MiCheck®在全球最大的医疗市场里实现商业化的又一重大里程碑。 Minomic的CEO，Brad Walsh博士表示：“能够和Cirrus Dx合作，让MiCheck®作为其实验室自研产品进入市场，这将给我们带来三个重大的收获：第一，获得更多真实病患的数据，有助于未来申报FDA认证；第二，进一步证明MiCheck® 在临床实用上的优越性能；第三，能够为公司带来销售收入。我们感谢Cirrus Dx的团队，特别是Kyle Ar
Mon Feb 18, 2019 04:00
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου